Randomized trial from the Lissoni group evaluating tamoxifen plus melatonin in heavily pretreated metastatic breast cancer.
Melatonin
Melatonin is a pineal and tissue-derived circadian hormone best known for sleep timing. In cancer discussions it is studied for circadian biology, antioxidant and mitochondrial effects, immune signaling, possible treatment-toxicity reduction, and light-at-night disruption. It is not a stand-alone cancer treatment. Connection to Cancer Melatonin is a hormone and signaling molecule produced by the pineal gland at night.
Randomized placebo-controlled trial of melatonin after lung cancer resection, relevant to recurrence, mortality, quality of life, sleep, mood, and fatigue outcomes.
Review of nocturnal melatonin, light at night, diet/metabolic signaling, and breast cancer growth mechanisms.
Systematic review/meta-analysis examining melatonin for quality of life, sleep, fatigue, nausea, and symptoms in cancer patients.
Cochrane plain-language summary noting uncertainty in robust evidence while describing possible fatigue and nausea benefits and safety limitations.
MSK herb/supplement monograph on melatonin, evidence, cancer-related studies, sleep, cachexia, safety, and interactions.
Review of melatonin as a possible radiosensitizer and radioprotective adjunct, noting few human clinical trials.
CancerChoices review of melatonin as a complementary cancer therapy, emphasizing that it is not first-line treatment while summarizing supportive clinical evidence.
Review of melatonin, light-at-night disruption, circadian signaling, tumor metabolism, and breast cancer biology.
JCO review connecting melatonin mechanisms, chemoprotection/radioprotection, and early clinical cancer literature.
NCCIH safety and evidence overview for melatonin, including advice for people diagnosed with cancer to consult their health care providers.
NCI/OCCAM summary on melatonin, circadian rhythm, sleep, chronotherapy, and cancer therapy context.
Systematic review and meta-analysis of randomized trials of melatonin in cancer patients, including tumor response, survival, and treatment-related side effects.
Clinical trial evaluating melatonin for chemotherapy-induced toxicity in patients with metastatic solid tumors.